However, the clinical implementation of FGF21-based therapies for the treatment of obesity is restricted by the complexity of pathophysiology of FGF21, the potential development of FGF21 resistance in obesity and the poor pharmacokinetic of native FGF2120–24. The gene discussed is FGF21; the disease is obesity due to melanocortin 4 receptor deficiency.